Abstracts tagged "risk and vasculitis"

Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting
Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 877 • 2015 ACR/ARHP Annual Meeting
Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study
Ju Ann¹, Hyon K. Choi², Sharan K. Rai³, Eric C. Sayre⁴ and J Antonio Avina-Zubieta^5,6, ¹Experimental Mediine, University of British Columbia, Richmond, BC, Canada, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada, Richmond, BC, Canada, ⁵Arthritis Research Canada / University of British Columbia, Vancouver, BC, Canada, ⁶Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is associated with an increased risk of mortality. However, recent mortality trends in GPA are largely unknown, particularly in the…
Abstract Number: 1769 • 2014 ACR/ARHP Annual Meeting
Abdominal Visceral Adipose Tissue Measured By DXA As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides
Bertrand Dunogué¹, Karine Briot², Sami Kolta³, Alexis Regent⁴, Pascal Cohen⁵, Alice Berezne⁶, Xavier Puéchal⁵, Claire Le Jeunne⁵, Luc Mouthon⁵, Christian Roux⁷, Loïc Guillevin for the French Vasculitis Study Group⁵ and Benjamin Terrier⁸, ¹Internal Medicine, Hôpital Cochin, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology B, Paris Descartes University, Cochin hospital, Paris, France, ⁴Internal Medicine, Institut Cochin, INSERM U1016, CNRS UMR 8104, Université Paris Descartes, Paris, France, Paris, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁷Paris Descartes University, Cochin Hospital, Paris, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose Studies have shown a strong prevalence of cardiovascular events among patients with primary necrotizing vasculitides. Recent studies indicate that visceral adipose tissue (VAT) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].